View Clinical Trial (Medical Research Study)
Metabolic Effects of Valproate and Antipsychotic Therapy
| City: |
|
St. Louis |
| State: |
|
Missouri |
| Zip Code: |
|
63110 |
| Conditions: |
|
Schizophrenia |
| Purpose: |
|
This study will determine the metabolic processes responsible for high levels of blood
glucose, metabolism disorders, and weight gain in people with schizophrenia who have been
treated with antipsychotic medications in combination with valproate.
|
| Study Summary: |
|
This project aims to study the whole-body metabolic processes responsible for hyperglycemia,
dyslipidemia and increased adiposity in schizophrenia patients treated with antipsychotic
medications in combination with valproate. The project hypothesizes that combined treatment
with valproate and antipsychotic medications will decrease insulin sensitivity at the level
of skeletal muscle, liver and adipose tissue, in comparison to antipsychotic monotherapy.
The decrease in insulin sensitivity is hypothesized to be associated with defects in glucose
and lipid metabolism and increased adiposity
Treatment effects of antipsychotic/valproate combination therapy on different components of
insulin secretion and action, and treatment effects on abdominal versus peripheral
adiposity, are unknown despite the availability of gold-standard methods and the prognostic
significance of these issues. Relevant data are needed to target basic research, to identify
the potential for acute and long-term complications, and to plan therapeutic interventions.
The following specific aims will be addressed in non-diabetic schizophrenia patients treated
with atypical antipsychotics who will be randomized to open label treatment with either
valproate or no adjuvant. Evaluations are performed at baseline and 3 months of treatment.
|
| Criteria: |
|
Inclusion Criteria:
- Meets DSM-IV criteria for schizophrenia, any type, treated with the same
antipsychotic for at least 6 months
- No antipsychotic medication dose changes for 1 month, and no other medication changes
for 1 month prior to study entry
Exclusion Criteria:
- Meets DSM-IV criteria for substance abuse within 3 months of study entry
- Involuntary legal status (as per Missouri law)
- Any serious medical disorder that may confound the assessment of relevant biologic
measures or diagnosis, including: significant organ system dysfunction, metabolic
diseases, type 1 or 2 diabetes mellitus, pregnancy, endocrine disease, coagulopathy,
anemia, or acute infection
- Currently taking more than one antipsychotic medication
- Currently taking prescription medications (except certain psychotropic medications as
discussed below), including oral contraceptive pills, any glucose lowering agent,
lipid lowering agent, exogenous testosterone, recombinant human growth hormone, or
any other endocrine agent that might confound substrate metabolism
|
| NCT ID: |
|
NCT00167934 |
| Primary Contact: |
|
Principal Investigator
Dan W. Haupt, MD
Washington University School of Medicine
Martha J. Hessler, BS
Phone: 314-362-2423
Email: hesslema@psychiatry.wustl.edu
|
| Backup Contact: |
|
Email: schweigj@psychiatry.wustl.edu
Julie Schweiger
Phone: 314-362-3153
|
| Location Contact: |
|
St. Louis, Missouri 63110
United States
Elizabeth T Westerhaus, MA
Phone: 314-747-1134
Email: westerhe@psychiatry.wustl.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 21, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|